got it
Artrya's core proprietary solution Salix has been admitted by the Thereapeutic Good Administration (TGA) as a Class 1 product, meaning it is free to be commercialised and licensed in Australia.
The funds from the IPO will go towards further research and development, as well as supporting international expansion in 2022 with regulatory approval applications already filed with the US Food and Drug Administration (FDA), with other regulatory filings to be made in the near future in Canada, the EU and the UK.
got itArtrya's core proprietary solution Salix has been...
Add AYA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
-0.020(5.71%) |
Mkt cap ! $25.98M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.0¢ | 33.0¢ | $13.56K | 40.46K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7083 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 50000 | 1 |
View Market Depth
| Last trade - 13.20pm 09/10/2024 (20 minute delay) ? |
| AYA (ASX) Chart |